Beste Hämatologe-Onkologen - TOP-349 Ärzte

Biography

Dr. Mehdi Afrit is a Medical Oncologist who practices at Burjeel Specialty Hospital in Sharjah. He has over 11 years of experience caring for and managing cancer patients. He has extensive experience providing chemotherapy, hormonal therapy, immunotherapy, and targeted therapy to patients. He earned a Certificate of Medical Oncology from the Gustave Roussy Institute in Paris, France, where he received training in antitumor chemotherapy and cancer medical treatment. Additionally, he holds an international certificate in breast diseases. He also has a certificate in Good Clinical Practice from Trans Celerate Biopharma Inc. and a certificate in Clinical Trial Management: Good Clinical Practice from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He previously worked for over five years as an Assistant Professor of Medical Oncology at Tunis’s Faculty of Medicine. He later practiced as a Consultant, Medical Oncologist for six years at Arianna’s hospital in Tunisia. He later worked for two years as a Specialist Medical Oncologist at Zulekha Hospital. He was also an investigator in three international clinical trials and holds clinical trial auditing and CRO certifications and a GCP Training Certificate from 2016. He is a member in good standing of the Emirates Oncology Society (EOS), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). His clinical expertise includes but is not limited to the following:

• Oncology care and treatment for chemotherapy, hormonal therapy, immune therapy, and target therapy
• Breast cancer
• Solid tumor diagnosis
• Digestive cancer
• Gynecological cancer
• Lung cancer
• Genitourinary cancer
• Sarcoma

Awards & Achievements

• Award from Himaya Foundations and University of Sharjah

Research & Publications

• Clinicopathological Features of Gastric Cancer in a Cohort of Gulf Council Countries' Patients: A Cross-Sectional Study of 96 Cases. Journal of Oncology Research Reviews & Reports Volume 2(2): 1-3.
• The Burden of Gynecologic Cancers in the UAE. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The Emirates Oncology Task Force Clinical Practice Guideline on Screening for SARS-CoV-2 in Asymptomatic Adult Cancer Patients Before Anti-Cancer Therapy. Journal of Oncology Research Reviews & Reports Volume 2(4): 1-6.
• The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Humaid Al-Shamsi, Humaa Darr, Ibrahim Abu-Gheida , Jawaher Ansari, Martine, Mehdi Afrit, Mohamad H Masri, Mohamed Abuhaleeqa. Gulf J Oncology 2020 Jan;1(32):71-87.
• Primary Bone Lymphoma: Tunisian Multicentric Retrospective Study About 32 Cases. Ben Ayed C, Laabidi S, Said N, Afrit M, Ben Ahmed S, Boussen H. Tunis Med. 2018 May;96(5):269-272.
• First Site of Recurrence After Breast Cancer Adjuvant Treatment in the Era of Multimodality Therapy: Which Imaging for Which Patient During Follow-up? Nesrine M, Mehdi B, Houda EB, Soumaya L, Mehdi A, Bechir Z, Hamouda B. Breast Dis. 2017 Nov 21

Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.

He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977. 

In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa. 

Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University. 

Current Positions: 

• .Since 1997, he is the Director of the Department of Medical Oncology and Haematology, at Istituto Clinico Humanitas, Milan. Also, he is Member of the Ethics Committee of Istituto Clinico Humanitas and Director of Clinical Research in the same Institute since 2007.
• - Since 2008, he is Member of the Planning Committee, Ministry of Work and of Health and Social Politics, Rome, Italy.
• - Since October 2008, Professor Santoro is Counsellor of the Board of Directors of the Fondazione Humanitas for Research of Rozzano, Italy.
• - Since November 2008, he is Expert Member of the National Centre for the Prevention and Control of Disease, Ministry of Work and of Health and Social Politics (Rome, Italy).
• - Since February 2009, he is National Representative preparatory actions for the "European Partnership for Action against Cancer" Ministry of Work and of Health and Social Politics (Rome, Italy).
• - Since February 2009, Professor Santoro is member of National Italian Committee on the Research Network in Oncology, Ministry of Work and of Health and Social Politics (Rome, Italy).
• - Since May 2009, he is Coordinator of the Oesophageal-Stomach Cancer Group Coordinator of the Liver and Biliary Tree Cancer Group, Regional Oncology Commission – Lombardy Oncology Network.

In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009). 

Publications: santoro%a - Search Results - PubMed (nih.gov)